Colon News and Research

RSS

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

IsoRay, Inc., announced today that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer.

21 Jan 2010

CPRIT awards the first $61M in grants for cancer research

The Cancer Prevention and Research Institute of Texas (CPRIT) awarded on January 20th the first $61 million in grants for cancer research projects at academic institutions and private companies throughout Texas. These are the inaugural grants of the $3 billion to be invested in cancer research in Texas over the next ten years.

21 Jan 2010

Genomic Health announces global commercial availability of its Oncotype DX colon cancer test

Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.

21 Jan 2010

Abaxis' new CRP assay receives FDA marketing clearance

Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced that the U.S. Food and Drug Administration (FDA) has granted 510K marketing clearance of the new C-Reactive Protein (CRP) assay when used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.

21 Jan 2010

UnitedHealth Group announces its revenues and net earnings in 2009

UnitedHealth Group today reported growth in revenues and net earnings per share in 2009. The Company earned $0.81 per share in the fourth quarter, bringing full year 2009 net earnings to $3.24 per share.

21 Jan 2010

IMUC’s ICT-107 vaccine product candidate targets cancer stem cells

ImmunoCellular Therapeutics today announced the results of a study in which it was shown that certain specific antigens are highly expressed on cancer stem cells (CSCs). This suggests that IMUC’s lead cancer vaccine product candidate ICT-107, which targets those antigens, may effectively target not only the cells that make up the bulk of certain cancerous tumors, but also the CSCs that are widely believed to give rise to them and cause their recurrence.

21 Jan 2010

Given Imaging includes Aptina’s image sensor in its PillCam capsule

Aptina announced today that Given Imaging Ltd.’s PillCam® COLON 2 includes Aptina’s MT9S526 medical image sensor. All three of Given Imaging’s patient-friendly, ingestible PillCam® products for small bowel, esophageal, and now colon imaging include Aptina’s sensors embedded within the Given Imaging capsules.

21 Jan 2010

European Patent Office grants a patent for Rexahn Pharmaceuticals' RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.

20 Jan 2010

Research article examining the use of acupuncture to prevent PPOI published

A research article to be published on January 7 , 2010 in the World Journal of Gastroenterology addresses this question. In this prospective randomized clinical trial, the authors examined if acupuncture could prevent prolonged postoperative ileus (PPOI) after intraperitoneal surgery among patients with colon cancer in Shanghai, China.

18 Jan 2010

Breast cancer and ovarian cancer tests not appropriate for all women, say experts

A genetic mutation can significantly increases a woman's risk of developing breast cancer and ovarian cancer. But does that mean everyone should be tested?

18 Jan 2010

Hyperphosphatemia following standard OSP doses is related to weight, reveals study

Colon cleansing is used widely for colonoscopic exploration and colonic and gynecological surgery. Oral sodium phosphate (OSP) solution is the osmotic laxative most commonly used for this purpose. It is known that OSP can induce severe hyperphosphatemia and hypocalcemia due to excessive absorption of phosphates, and there have been reports of deaths and irreversible dialysis-requiring renal insufficiency. However, no prospective studies have investigated the prevalence of hyperphosphatemia in low-risk patients.

18 Jan 2010

Surveillance colonoscopy need to be better aligned with patients' risks for colorectal cancer

How often patients receive surveillance colonoscopy may need to be better aligned with their risks for colorectal cancer, according to two papers published this month by University of Pittsburgh School of Medicine researchers.

18 Jan 2010

Treatment for metastatic tumor based on its unique protein makeup

Imagine if treatments for disease could be based not on a patient's diagnosis but instead on the characteristics of their tissue. By identifying and decoding the cryptic messages hidden deep inside the human proteome, scientists and physicians who study personalized medicine are seeking more effective treatments and disease management for patients.

18 Jan 2010

Study results show increase of mortality due to colon cancer in Spain

There are stark geographical contrasts in the incidence of colon cancer worldwide. The new study analyses the causes of these disparities, starting with Spanish trends between 1951 and 2006 in terms of certain changes in consumption (tobacco, alcohol, red and processed meat, fish, vegetables...) and also behaviour (physical exercise, sedentary lifestyles-).

18 Jan 2010

Dr. Michel Kahaleh uses pCLE technique to diagnose and treat cancer

The world's smallest flexible microscope is diagnosing some big diseases and allowing physicians to treat patients on the spot. Dr. Michel Kahaleh, associate professor of medicine in the Division of Gastroenterology and Hepatology at the University of Virginia Health System, is the only physician in Virginia currently using probe-based confocal laser endomicroscopy (pCLE).

18 Jan 2010

Scientists discover potential biomarkers to predict the spread of colon cancer

Scientists in China are reporting discovery of two proteins present in the blood, of people with colon cancer that may serve as the potential biomarkers for accurately predicting whether the disease will spread.

18 Jan 2010

Zassi Medical Evolutions forms new company to develop electrical stimulation technology

Zassi Medical Evolutions, a privately held organization that innovates, designs and develops high technology medical devices and software announced today that it has successfully spun out and formed a new company with Tucson, Arizona based Research Corporation Technologies (RCT) to pursue the continued development of a novel electrical stimulation technology for the gastrointestinal continence control market.

13 Jan 2010

First sulfite-free rectal suspension for UC

sfRowasa™ (mesalamine) Rectal Suspension 4g/60mL –Sulfite-Free Formulation, is the first sulfite-free rectal suspension available for Ulcerative colitis (UC). According to a study published in The American Journal of Gastroenterology, products containing sulfites may exacerbate natural sulfide levels in the colon and may increase inflammation in UC patients. With its sulfite-free preparation, sfRowasa™ offers a new treatment option for the treatment of active, mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.

13 Jan 2010

Mango effective against colon and breast cancer

Mango. If you know little about this fruit, understand this: It's been found to prevent or stop certain colon and breast cancer cells in the lab.

12 Jan 2010

Experiments show Alzheimer's drug may halt the growth of oesophageal cancer

Cancer of the gullet, or oesophagus, is one of the ten most common cancers in the Western world, and there have been recent alarming increases in the number of cases each year in the US and UK.

12 Jan 2010